期刊文献+

内源性表达白细胞介素21的CIK细胞的抗白血病作用及其机制 被引量:8

Effects and mechanism on anti-leukemic activity of cytokine-induced killer cells with an endogenousexpression of interleukin-21
原文传递
导出
摘要 目的研究内源表达白细胞介素2l(IL-21)对外周血来源的细胞因子诱导的杀伤细胞(CIK细胞)抗自血病的作用及其作用机制。方法采集分离健康人外周血单个核细胞,加用细胞因子诱导培养CIK细胞,构建表达IL-21基因的慢病毒载体,感染CIK细胞并鉴定后,四甲基偶氮唑盐(Mqq")法检测CIK细胞的增殖能力及杀伤白血病细胞系K562细胞作用;半定量反转录(RT)-PCR法检测CIK细胞干扰素1(IFN-y)、肿瘤坏死因子0(TNF.OL)、TNF.B、穿孔素、颗粒酶A、颗粒酶B、Fas配体(FasL)和NKG2D分子(NKG2D)的mRNA表达;流式直接免疫标记法检测CIK细胞免疫表型、细胞表面IL-21受体(IL.21R)、FasL及细胞内穿孔素、颗粒酶B的表达;酶联免疫法检测培养上清中IFN-^v和TNF-OL的表达。结果经酶切与测序鉴定,IL-21慢病毒载体构建正确,共转染CIK细胞中有目的基因IL-21的表达。(1)与空载体组相比,内源表达IL-21组总的细胞增殖之间差异无统计学意义(P=0.856),内源表达IL-21组CIK细胞阳性细胞数高于空载体组(24.60%±2.10%比16.95%±4.70%,P=0.042)。(2)内源表达IL.21组CIK细胞对K562细胞的杀伤率高于空载体组(58.4%±8.3%比23.3%±2.8%,P=0.009),作用第5天时,杀伤作用仍能维持在61.2%±6.2%(P:0.003),相比外源性IL-21作用的CIK细胞的杀伤率(44.6%±8.3%比22.8%±2.8%,P=0.034)更强,而且作用时间更长久。(3)内源表达IL-21组CIK细胞表面IL-21R的表达比空载体组增加约2倍。(4)与空载体组比较,内源表达IL-21组CIK细胞IFN--,/和TNF-仪mRNA的表达升高约1.5倍,穿孔素、颗粒酶B、FasLmRNA的表达量升高近2倍,颗粒酶A、TNF-B和NKG2DmRNA的表达与空载体组差异无统计学意义。(5)对mRNA表达差异有统计学意义的指标进-步行蛋白质表达的检测发现:内源表达IL-21组CIK细胞表面FasL、穿孔素、颗粒酶B、IFN-y、TNF-a的表达水平均高于空载体组0.56%±0.37%比0.06%±0.02%、25.86%±6.13%比12.23%-4-2.35%、37.58%±2.30%比14.56%±1.36%、(55.3±3.5)ng/L比(23.2±5.6).g/L、(15.6±0.6)斗∥L比(5.6±0.6)μg/L,均P〈0.05]。结论内源表达IL,21的CIK细胞具有更强的抗白血病作用,而且作用时间更长久,此作用可能是通过增加其受体的表达,增加穿孔素、颗粒酶B、FasL、IFN-y和TNF-a. Objective To explore the effects and mechanism on anti-leukemic activity of cytokine inducing killer (CIK) cells with an endogenous expression of interleukin-21 (IL-21). Methods Mononuclear cells were isolated from peripheral blood and cultured with cytokines to generate CIK cells.IL-21 lentiviral vector was constructed and used to transfect 293T cells. Then the culture supernatant with virus infected CIK cells was identified. Proliferation of CIK cells and their cytotoxic activity against K562 cells were measured by methyl thiazolyl tetrazolium ( MTT ). The expressions of interferon-y ( IFN-y), tumor necrosis factor-a(TNF-ca) , tumor necrosis factor-β(TNF-β) , perforin, granzyme A, granzyme B, FasL and NKG2D mRNA were measured by semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR). Immunophenotypes of CIK cells, IL-21 receptor (IL-21R) and FasL on the surface of CIK cells, intra-cellular perforin and granzyme B of CIK cells were measured by flow eytometry. And the concentrations of IFN-a/and TNF-ot in cultured supernatant were measured by enzyme immunoassay. Results By restriction enzyme digestion and sequencing, IL-21 lentiviral vector was identified, after transfecting virus surpernatant into CIK cells, the expression of IL-21 was detected in CIK cells. Compared to control, (1) the total number of cells remained unchanged, but the proportion of cells expressing CD3 +/CD56+ phenotype increased from 16. 95%±4. 70% to 24. 60%± 2. 10% . (2) Cytotoxic activity against K562 cells by CIK cells increased from 23.3%±2. 8% to 58. 4%±8.3% and stayed at 61.2%±6. 2% after 5 days. It was stronger and longer compared to the exogenous effect of IL-21 ( from 22. 8%±2. 8% to 44. 6%±8.3% ). (3) The expression of IL-21R increased around 2 folds. (4) The mRNA expressions of IFN-y, and TNF-ct increased almost I. 5 folds, perforin, granzyme B, FasL rose almost 2 folds, the expressions of granzyme A, TNF-~ and NKG2D were similar with those of controls. ( 5 ) Detected by flow cytometry, the expression of FasL of CIK cells was higher than that of control (0. 56%±0. 37% vs 0. 06% ±0. 02% ) , the expression of perforin increased from 12. 23%±2. 35% to 25.86%±6. 13% , the expression of granzyme B rose from 14. 56%±1.36% to 37.58%±2. 30%, the concentration of IFNy in culture supernatant spiked from (23.2 ±5.6) to (55.3±3.5) ng/L and TNF-a jumped from (5.6±0. 6) to (15. 6 ± O. 6 ) μg/L. Conclusions CIK cells with an endogenous expression of IL-21 have stronger anti- leukemic activity through an up-regulation of IL-21 R, perforin, granzyme B, FasL, IFN-y, and TNF-y Thus IL-21 mac potentially enhance the anti-leukemic immunotheraDv.
出处 《中华医学杂志》 CAS CSCD 北大核心 2013年第4期293-299,共7页 National Medical Journal of China
基金 国家自然科学基金(81041043) 教育部留学归国人员科研启动基金(教外司留[2007]1108) 天津币卫生局科技基金重点项目(2011KR01)
关键词 白血病 细胞因子诱导杀伤细胞 白细胞介素21 抗白血病作用 Leukemia Cytokine-induced killer cells Interleukin-21 Anti-leukemic effects
  • 相关文献

参考文献13

  • 1Parrish-Novak J,Dillon SR,Nelson A. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function[J].Nature,2000.57-63.
  • 2Monteleone G,Pallone F,Macdonald TT. Interleukin-21 (IL-21)-mediated pathways in T cell-mediated disease[J].Cytokine & Growth Factor Reviews,2009.185-191.
  • 3赵明峰,翟文静,邓琦,李玉明,耿丽,杨莉,吕海容,林雪梅,刘鹏江,李敬兰.白介素21对树突状细胞诱导的CTL抗白血病作用的影响[J].中国实验血液学杂志,2009,17(3):627-632. 被引量:5
  • 4赵明峰,邓琦,李玉明,林雪梅,刘鹏江,耿丽,李敬兰.人源白细胞介素21对外周血及脐血来源CIK细胞产生和抗肿瘤活性的作用研究[J].中国免疫学杂志,2008,24(9):794-799. 被引量:7
  • 5Zhao MF,Deng Q,Li YM. Interleukin 21 enhances the expansion and anti-tumor cytotoxic activity of cytokine-induced killer cells derived from both peripheral blood and cord blood in vitro[C/OL]//ASH annual meeting[J].Blood,2007.4887.
  • 6Hashmi MH,Van Veldhuizen PJ. Interleukin-21:updated review of Phase Ⅰ and Ⅱ clinical trials in metastatic renal cell carcinoma,metastatic melanoma and relapsed/refractory indolent nonHodgkin's lymphoma[J].Expert Opinion on Biological Therapy,2010.807-817.
  • 7赵明峰.IL-21——一种新的免疫系统调节因子[J].国际免疫学杂志,2008,31(5):360-364. 被引量:7
  • 8Andorsky DJ,Timmerman JM. Interleukin21:biology and application to cancer therapy[J].Expert Opinion on Biological Therapy,2008.1295-1301.
  • 9Davis ID,Brady B,Kefford RF. Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage Ⅳ malignant melanoma without prior treatment:a phase Ⅱ a trial[J].Clinical Cancer Research,2009.2123-2129.
  • 10Meazza R,Azzarone B,Orengo AM. Role of commongamma chain cytokines in NK cell development and function:perspectives for immunotherapy[J].Journal of Biomedicine and Biotechnology,2011.861920.

二级参考文献68

  • 1许晓群,张建(审校者).白细胞介素21免疫学效应研究进展[J].国际免疫学杂志,2006,29(1):34-37. 被引量:3
  • 2陈绍倩,杜英,王鑫,顾巧丽,黄玉敏,董子明.K562细胞外泌体诱导特异性CTL生成的研究[J].中国实验血液学杂志,2006,14(6):1168-1171. 被引量:7
  • 3邓琦,李学敏,赵明峰,李玉明.急性白血病RNA转染脐血源性树突状细胞介导的免疫作用[J].临床荟萃,2007,22(2):80-83. 被引量:1
  • 4Parrish-Novak J, Dillon SR, Nelson A, et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature, 2000, 408 (6808) :57-63.
  • 5Habib T, Senadheera S, Weinberg K, et al. The common gamma chain (gamma c) is a required signaling component of the IL-21 receptor and supports IL-21-induced cell proliferation via JAK3. Biochemistry, 2002, 41 (27) :8725-8731.
  • 6Brandt K, Bulfone-Paus S, Foster DC, et al. Interleukin-21 inhibits dendritic cell activation and maturation. Blood, 2003, 102 (12) :4090-4098.
  • 7Gowda A, Roda J, Hussain SR, et al. IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro. Blood, 2008, 111(9) :4723-4730.
  • 8Scheeren FA, Diehl SA, Smit LA, IL-21 is expressed in Hodgkin lymphoma and activates STAT5: evidence that activated STAT5 is required for Hodgkin lymphomagenesis. Blood, 2008, 111 (9) : 4706-15.
  • 9Coquet JM, Kypafissoudis K, Pellicci DG, el al, IL-21 is produced by NKT cells and modulales NKT cell activation and cytokine production. J Immunol, 2007,178 (5) :2827-2834.
  • 10Strengell M, Matikainen S, Siren J, et al. IL-21 in synergy with IL-15 or IL-18 enhances IFN-gamma production in human NK and T cells. J Immunol, 2003,170( 11 ) :5464-5469.

共引文献11

同被引文献56

  • 1赵静,郭子宽,许中伟.CAR-T细胞治疗在儿童白血病治疗中的应用[J].中国小儿血液与肿瘤杂志,2020(3):121-125. 被引量:4
  • 2刘军权,陈复兴,巩新建,周忠海,王涛.茶多酚对人细胞因子诱导的杀伤细胞和胃癌细胞株作用观察[J].东南国防医药,2003,5(2):81-83. 被引量:2
  • 3王家祥,郑树,刘秋亮.不同来源CIK细胞的体外扩增和杀伤活性的比较[J].第四军医大学学报,2005,26(7):616-618. 被引量:26
  • 4袁玉涛,王志华,秦莉,张春艳,马玉彦,孙喜文.IL-24对细胞因子诱导的杀伤细胞的作用[J].世界华人消化杂志,2007,15(6):548-553. 被引量:9
  • 5Linn YC,Wang SM,Hui KM,et al.Comparative gene expression profiling of cytokine-induced killer cells in response to acute myloid leukemic and acute lymphobastic leukemic stimulators using oligonucleotide arrays[J].Exp Hemato1,2005,33 (6):671-681.
  • 6Wang Y,Bo J,Dai HR,et al.CIK cells from recurrent or refractory AML patients can be efficiently expanded in vitro and used for reduction of leukemic blasts in vivo[J].Exp Hematol,2013,41 (3):241-252.
  • 7Hoyle C,Bangs CD,Chang P,et al.Expansion of Philadelphia Chromosome-Negative CD3+ D56 + Cytotoxic Cells From Chronic Myeloid Leukemia Patients:In Vitro and In Vivo Efficacy in Severe Combined Immunodeficiency Disease Mice[J].Blood,1998,92(9):3318-3327.
  • 8Nishimura R,Baker J,Beihack A,et al.In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity[J].Blood,2008,112 (6):2563-2574.
  • 9Uhlin M,Okas M,Gertow J,et al.A novel haplo-identical adoptive CTL therapy as a treatment for EBV-associated lymphoma after stem cell transplantation[J].Cancer Immunol Immunother,2010,59 (3):473-477.
  • 10Grupp SA,Kalos M,Barrett D,et al.Chimeric antigen receptor-modified T cells for acute lymphoid leukemia[J].N Engl J Med,2013,368(16):1509-1518.

引证文献8

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部